Eli Lilly's Zepbound Price Hike
This is a Zepbound news story, published by Ars Technica, that relates primarily to Zepbound news.
Zepbound news
For more Zepbound news, you can click here:
more Zepbound newsZepbound news
For more Zepbound news, you can click here:
more Zepbound newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsArs Technica news
For more news from Ars Technica, you can click here:
more news from Ars TechnicaAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Pharmaceutical giant Eli Lilly. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug pricing news, dosage news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
loss drug tirzepatideArs Technica
•Eli Lilly raises price of Zepbound while trumpeting discount on starter vials
76% Informative
Eli Lilly announced Tuesday that it is now selling starter dosages of its weight-loss drug tirzepatide ( Zepbound ) at a price significantly lower than before.
But critics quickly noticed that the company also quietly raised the price on current versions of the drug.
In the past, Lilly sold Zepbound only in injectable pens with a list price of $ 1,060 for a month 's supply.
VR Score
76
Informative language
75
Neutral language
7
Article tone
semi-formal
Language
English
Language complexity
39
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
7
Source diversity
6
Affiliate links
no affiliate links